For novaluron, the Authority submitted a reasoned opinion on the review of the existing MRLs in accordance with Article 12(1) of Regulation (EC) No 396/2005 [European Food Safety Authority; Reasoned opinion on the review of the existing maximum residue levels for novaluron according to Article 12 of Regulation (EC) No 396/2005. EFSA Journal 2022;20(1):7041.]. In view of various data gaps on toxicologically relevant issues, including uncertainties regarding possible endocrine disruptor properties of that active substance, the Authority could not rule out harmful effects on human health with the MRLs for novaluron in all products. It is therefore appropriate to set the MRLs for all products at the LODs specific to each product in Annex V to Regulation (EC) No 396/2005.
Recital 5, Regulation (EU) 2023/466
In forcesince 3 Mar 2023